Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Remain Fit: Powerful Wellness and Work-out Schedules for a Better You - 2Tech for Efficiency: Applications and Apparatuses to Accomplish More
- 3RFK Jr. wants to scrutinize the vaccine schedule – but its safety record is already decades long
- 4Former 'Bachelorette' welcomes 1st baby via emergency c-section
- 5Farewell, comet 3I/ATLAS! Interstellar visitor heads for the outer solar system after its closest approach to Earth
- The most effective method to Shake Hands Expertly: A Bit by bit Guide
- A definitive Frozen yogurt Standoff: Which Flavor Rules?
- The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- How did I get my own unique set of fingerprints?
- Novartis eyes more bolt-on acquisitions, CEO says
- Russia’s New KVS Drone May Be Designed To Restore Reach In The FPV War
- 6 Methods for further developing Rest Quality
- Brazil judge orders government to add JBS subsidiary to 'dirty list' for slavery
- Tesla plans to expand production at German car plant
